Summary
The authors provide general advice on the use of the ultrasound contrast agent Sonazoid and intend to create standard protocols for its use and administration in hepatic and pancreatobiliary applications in Asian patients.
The authors note that the third edition of the contrast-enhanced ultrasound (CEUS) guidelines did not include specific recommendations for the use of Sonazoid, as its clinical experience was limited to Japan and Korea.
In this paper, they aim to provide general advice on the use of Sonazoid and create standard protocols for its use and administration in hepatic and pancreatobiliary applications in Asian patients.
